Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.24 and traded as low as $0.1506. bioAffinity Technologies shares last traded at $0.1650, with a volume of 2,000 shares.
bioAffinity Technologies Stock Performance
The firm’s 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $0.24.
About bioAffinity Technologies
bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for the early detection of lung cancer and other diseases. Its work combines cellular analysis and other diagnostic technologies to support earlier identification of disease. The company’s lead product, CyPath Lung, is a diagnostic test that analyzes sputum samples using flow cytometry to help assess the likelihood of lung cancer. The test is processed through Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
